​

Benitec Biopharma Stock (NASDAQ:BNTC)

ForecastRevenueOwnershipFinancialsChart
Benitec Biopharma by TradingView

Previous Close

$10.76

52W Range

$2.70 - $13.29

50D Avg

$11.06

200D Avg

$9.35

Market Cap

$252.36M

Avg Vol (3M)

$54.31K

Beta

0.88

Div Yield

-

BNTC Company Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

16

IPO Date

Jun 24, 2014

Website

BNTC Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceJun 23Jun 22Jun 20
License$75.00K$73.00K-
Grant--$5.00K

Fiscal year ends in Jun 24 | Currency in USD

BNTC Financial Summary

Jun 24Jun 23Jun 22
Revenue-$75.00K$73.00K
Operating Income$-22.49M$-19.08M$-17.85M
Net Income$-22.37M$-19.56M$-18.56M
EBITDA$-22.49M$-18.73M$-17.93M
Basic EPS$-0.01$-14.12$-38.62
Diluted EPS$-0.01$-14.12$-38.62

Fiscal year ends in Jun 24 | Currency in USD

Latest Earnings Call Transcripts

Q3 18Jun 01, 18 | 5:00 PM

Peer Comparison

TickerCompany
NXTCNextCure, Inc.
ZVSAZyVersa Therapeutics, Inc.
CAPRCapricor Therapeutics, Inc.
APLMApollomics, Inc.
ALRNAileron Therapeutics, Inc.
BPTHBio-Path Holdings, Inc.
ZURAZura Bio Limited